Close menu




April 28th, 2022 | 13:00 CEST

BioNTech share price about to double? Varta and Meta Materials with newsflow, or not

  • Biotechnology
  • Technology
Photo credits: metamaterial.com

Those who are currently betting on rising prices on the stock market need strong nerves. But some companies are worth a closer look. Among others, this applies to BioNTech. The Company is facing important deadlines, continues to earn billions with its Corona vaccine and has an attractive product pipeline. The analysts at Berenberg, for example, see doubling potential after the stock has bottomed out. Meta Materials has also formed a bottom formation, and at the same time, there was positive newsflow from the developer of revolutionary products. Varta shareholders have been hoping for this for some time, but in vain. The share is battered, and even the current financial injection cannot change that.

time to read: 4 minutes | Author: Fabian Lorenz
ISIN: BIONTECH SE SPON. ADRS 1 | US09075V1026 , Meta Materials Inc. | US59134N1046 , VARTA AG O.N. | DE000A0TGJ55

Table of contents:


    Meta Materials: Science fiction becomes reality

    Metamaterials seem to turn physics on its head and have remarkable properties. They have nanostructures and can, for example, guide light around an object, making it invisible. And there are not only optical metamaterials. There are also acoustic ones that manipulate sound, thermal ones in which heat conduction is directed, and mechanical metamaterials, for example, solids that behave like liquids. It sounds like science fiction, but actual products are now emerging. One of the pioneers in this field is Meta Materials.

    The Canadians have developed a technology platform that uses artificial intelligence to produce high-performance functional materials and nanocomposites. The potential applications of the products are enormous - from electric vehicles to the Internet of Things, renewable energies, medicine and aerospace. In 2021, Meta Materials turned over USD 4.1 million, 264% more than the previous year. In addition, research and development is underway - 163 patents have been granted, and another 106 have been filed - and production capacity is being expanded. The Company is not yet making a profit, accordingly. Nor has there been anything to gain yet with the NASDAQ-listed stock. After peaking at USD 21.76 last summer, the share price fell sharply to USD 1.23. In the meantime, a bottom seems to have been found because, operationally, things are happening.

    In April, Meta went from strength to strength. First, the acquisition of Plasma App Ltd. was announced. The purchase price of 20 million Canadian dollars (CAD) was paid in shares at CAD 1.86. The acquisition is expected to increase production capacity significantly, increasing speed and reducing costs. In addition, Plasma App has an interesting technology in the field of battery materials. Meta has also received an interesting order from a central bank for CAD 2.2 million - Meta's subsidiary Nanotech Security is developing a unique security feature for cash. Meta Materials is also stepping on the gas in terms of personnel. A new experienced executive vice president has come on board to head the engineering and electro-optical and infrared systems department.

    In addition, George Francis, a manager with over twenty-five years of professional experience, has been recruited for the newly created position of Chief Information Officer. He will not only look after IT architecture and cybersecurity but will also look into the potential monetization of the data that Meta's new products are likely to generate. The stock has yet to react to the positive news flow, but that is likely only a matter of time.

    BioNTech on the verge of doubling in price?

    Shareholders of BioNTech have had little reason to rejoice in recent weeks. However, at least a bottoming out seems to be underway for the German biotech startup's stock. Previously, BioNTech had reported convincing figures and announced a share buyback and a special dividend. There should be potential for price swings in the coming weeks. The release of clinical data on the safety, tolerability and efficacy of a vaccine tailored to the Omicron variant is eagerly awaited. On May 9, BioNTech will also report on its operating performance for the first quarter of 2022. Most recently, Berenberg had also commented positively on BioNTech. Although the analysts have reduced the price target from USD 400 to USD 350, this would still mean more than a doubling of the price. Accordingly, they recommend the share as a buy. The Corona vaccine would continue to bring billions into the coffers, the product pipeline for infectious diseases is well filled, and the share is accordingly undervalued.

    Varta: 250 million promissory note for growth

    The Varta share is having a hard time bottoming out. This week, for example, it fell below the EUR 90 mark again. On March 31, the Group presented figures for the past fiscal year. There is currently a lack of positive impetus. Initially, the annual figures were not convincing. Varta increased sales by 3.8% to EUR 902.9 million in the past fiscal year. Adjusted EBITDA increased by 17.4% to EUR 282.9 million. In the current year, sales are expected to be between EUR 950 million and EUR 1 billion and EBITDA is expected to fall slightly.

    However, the Company said the forecast is fraught with question marks due to Russia's war of aggression and the impact of Corona on customers. The hope for management and shareholders is the V4Drive for use in electric cars. To this end, Varta has raised fresh capital and placed a EUR 250 million promissory note loan. Varta CTO Rainer Hald: "The plan is to use the money to expand our lithium-ion business. One focus will be on building up production capacities of the large-format round cell. In addition, the capacities of the small-format cells will also be further expanded." However, concrete customers or partners in the field of electromobility are still not forthcoming. Most recently, Warburg Research reduced its price target for Varta from EUR 113 to EUR 110.


    Strong nerves are needed on the stock market at the moment. But stocks like BioNTech, Varta and Meta Materials have future potential.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.


    Der Autor

    Fabian Lorenz

    For more than twenty years, the Cologne native has been intensively involved with the stock market, both professionally and privately. He is particularly passionate about national and international small and micro caps.

    About the author



    Related comments:

    Commented by Stefan Feulner on September 27th, 2022 | 11:45 CEST

    Evotec, Defence Therapeutics, Formycon - Biotech opportunity!

    • Biotechnology

    Due to the stricter monetary policy of the central banks and inflation concerns, the capital-intensive biotech sector is also suffering. The NASDAQ Biotechnology Index has lost almost a quarter of its value since the beginning of the stock market year. In addition, the number of companies trading even below their cash levels is higher than ever. At the same time, as can be seen with vaccine manufacturers, the industry is becoming increasingly important in everyday life. Especially in cancer research, some companies have the opportunity to multiply in the coming years based on their product pipeline.

    Read

    Commented by Nico Popp on September 27th, 2022 | 10:50 CEST

    Plug Power, dynaCERT, Varta: Where there is shadow, there is also light

    • Hydrogen
    • GreenTech
    • Technology

    GreenTech shares have been booming in recent weeks, and rightly so: regenerative energy sources and innovative drives are now often even cheaper than proven technology. Coupled with zero emissions, this is a decisive advantage. We explain why some shares are nevertheless weakening and show where there are interesting opportunities.

    Read

    Commented by André Will-Laudien on September 26th, 2022 | 11:36 CEST

    Favorable entries at Kion, Defense Metals, Nordex: The GreenTech rally is coming back soon!

    • Mining
    • RareEarths
    • GreenTech
    • Technology

    The daily analysis of stock market movements may not be an absolute joy for many investors at the moment. Nevertheless, in addition to numerous burdens, there are also bright spots. The warehouse logistics expert Kion is a long-term growth stock available now at 80% below its high. At rare earth explorer Defense Metals, initial drilling is delivering good results. GreenTech stocks JinkoSolar and Nordex should benefit from the boom in alternative energy generation for many years to come. As the saying goes, "Buy when the guns are roaring!" - they have been doing that for seven months now. Is the next rally already lurking around the corner?

    Read